Humira 市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、應用、配銷通路、地區和競爭細分，2020-2030 年

2024 年全球 Humira 市場價值為 104.1 億美元，預計到 2030 年將達到 198.4 億美元，預測期內的複合年成長率為 11.32%。由於類風濕性關節炎、乾癬性關節炎、克隆氏症、潰瘍性結腸炎和僵直性脊椎炎自體免疫性和慢性發炎疾病的盛行率不斷上升，市場正在穩步成長。隨著老年人口的成長和對早期診斷和治療認知的提高，Humira（阿達木單抗）等生物療法的使用越來越頻繁。 Humira 在減少發炎和改善長期疾病管理方面的有效性已被證實，這使其成為風濕病學、胃腸病學和皮膚病學等各個專業的首選治療方法。此外，透過探索新適應症和聯合療法的臨床試驗，它的用途正在不斷擴大。儘管關鍵專利已經到期，但該品牌仍然保持著強大的市場影響力，這得益於交付方式、患者援助計劃和戰略許可努力的創新，有助於減輕生物學名藥競爭的影響。

關鍵市場促進因素

自體免疫疾病和慢性發炎疾病盛行率上升

主要市場挑戰

專利到期和獨佔權喪失

主要市場趨勢

對真實世界證據 (RWE) 的需求不斷成長

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球 Humira 市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按產品（品牌藥、生物相似藥）
  • 依應用（類風濕性關節炎 (RA)、乾癬性關節炎 (PsA)、克隆氏症 (CD)、潰瘍性結腸炎 (UC)、僵直性脊椎炎等）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第6章：北美Humira市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲 Humira 市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區 Humira 市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美洲Humira市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲 Humira 市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如有）
• 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Alvotech
• Amgen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• CELLTRION INC.
• Coherus BioSciences, Inc.
• Fresenius Kabi AG
• FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sandoz Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

The Global Humira Market was valued at USD 10.41 Billion in 2024 and is projected to reach USD 19.84 Billion by 2030, growing at a CAGR of 11.32% during the forecast period. The market is witnessing steady growth, fueled by the increasing prevalence of autoimmune and chronic inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. With a growing elderly population and improved awareness around early diagnosis and treatment, biologic therapies like Humira (adalimumab) are being prescribed more frequently. Humira's proven effectiveness in reducing inflammation and improving long-term disease management has made it a preferred treatment across various specialties, including rheumatology, gastroenterology, and dermatology. Additionally, its usage is being extended through clinical trials exploring new indications and combination therapies. Despite the expiration of key patents, the brand continues to maintain a strong market presence, aided by innovations in delivery methods, patient assistance programs, and strategic licensing efforts that help mitigate the impact of biosimilar competition.

Key Market Drivers

Rising Prevalence of Autoimmune and Chronic Inflammatory Diseases

The increasing incidence of autoimmune and chronic inflammatory disorders is a primary factor driving the Global Humira Market. According to the World Health Organization, approximately 18 million people were living with rheumatoid arthritis in 2019, with a 14.1% increase in global age-standardized prevalence since 1990. In the United States alone, psoriasis affects about 3% of the adult population, totaling over 7.5 million individuals.

This expanding patient base fuels the demand for biologic treatments like Humira, especially as healthcare providers are beginning therapy earlier in the disease course to prevent long-term complications. Greater public awareness and advocacy have also contributed to earlier diagnosis and intervention, making advanced immunotherapies more integral to treatment strategies. Humira's long-standing clinical use across multiple therapeutic areas has established it as a trusted option among physicians, reinforcing its continued adoption.

Key Market Challenges

Patent Expirations and Loss of Exclusivity

One of the most significant challenges facing the Global Humira Market is the expiration of its key patents and the resulting loss of market exclusivity. AbbVie's Humira enjoyed a dominant position due to robust patent protection, but the introduction of biosimilar adalimumab products has begun to erode its market share. These biosimilars offer similar efficacy at lower prices, prompting healthcare systems-particularly in cost-sensitive regions-to encourage their use as a cost-saving measure.

As biosimilar availability expands, insurers and pharmacy benefit managers are prioritizing them over the originator drug, increasing pressure on prescribers to switch treatments. This competitive shift is changing pricing dynamics and weakening Humira's revenue potential in markets where cost containment and accessibility are key concerns.

Key Market Trends

Rising Demand for Real-World Evidence (RWE)

A growing focus on Real-World Evidence (RWE) is shaping the Global Humira Market, as stakeholders seek comprehensive data on how treatments perform outside controlled clinical trials. With the rise of biosimilars and competitive pricing, regulators, payers, and clinicians are relying more on RWE to evaluate long-term outcomes, adherence rates, patient satisfaction, and comparative effectiveness across various populations.

RWE provides valuable insights into how therapies function in real-world settings, especially for patients with multiple conditions or inconsistent treatment patterns. These insights are crucial for making informed decisions about therapy options, reimbursement policies, and value-based care initiatives, particularly as the market adapts to increasing biosimilar usage.

Key Market Players

• Alvotech
• Amgen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• CELLTRION INC.
• Coherus BioSciences, Inc.
• Fresenius Kabi AG
• FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sandoz Inc.

Report Scope:

In this report, the Global Humira Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Humira Market, By Product:

• Branded
• Biosimilar

Humira Market, By Application:

• Rheumatoid Arthritis (RA)
• Psoriatic Arthritis (PsA)
• Crohn's Disease (CD)
• Ulcerative Colitis (UC)
• Ankylosing Spondylitis
• Others

Humira Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Humira Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Humira Market.

Available Customizations:

Global Humira Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Humira Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Branded, Biosimilar)
  • 5.2.2. By Application (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis (UC), Ankylosing Spondylitis, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Humira Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Humira Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Humira Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Humira Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Humira Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Humira Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Humira Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Humira Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Humira Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Humira Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Humira Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Humira Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Humira Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Humira Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Humira Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Humira Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. South America Humira Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Humira Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Humira Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Humira Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Humira Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Humira Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Humira Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Humira Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Alvotech
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Amgen Inc.
• 15.3. Boehringer Ingelheim Pharmaceuticals, Inc.
• 15.4. CELLTRION INC.
• 15.5. Coherus BioSciences, Inc.
• 15.6. Fresenius Kabi AG
• 15.7. FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
• 15.8. Pfizer Inc.
• 15.9. Samsung Bioepis Co., Ltd.
• 15.10. Sandoz Inc.

16. Strategic Recommendations

17. About Us & Disclaimer